Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Luminate in Intermediate Non-Exudative AMD
NCT03626636Phase 2Completed
- Sponsor
- Allegro Ophthalmics, LLC
- Start
- Aug 2017
- Primary completion
- Apr 2019
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of risuteganib in age-related macular degeneration (AMD) (2 arms), sponsored by Allegro Ophthalmics, LLC. Primary endpoint: Change in Best Corrected Visual Acuity at 8 months. Started Aug 2017; status: completed.
02
Drugs
risuteganib
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NCT03626636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03626636.